Puma Biotechnology, Inc. PBYI
Set alert
10.08 USD -0.10 -0.98%
As of Nov 3, 10:46 AM ET
10.11 Day range 10.38
4.58 52-week range 11.50
- YTD
- +69.41%
- 1 year
- +100.00%
- Open
- 10.23
- Prev close
- 10.18
- Mkt cap
- 521.88M
- Vol
- 67.84K
- Avg vol
- 334.13K
- EPS
- 0.51
- P/E
- 19.82
- Div yield
- 0.00%
More statistics
- Low
- 10.11
- High
- 10.38
- Forward P/E
- 11.71
- Beta
- 1.08
- Short ratio
- 5.09
- Inst. own
- 67.74%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.94
- 200-d avg
- 3.58
- 1y target
- 4.33
Analyst view
Consensus: none
Price target (mean) 4.33 -57.0% downside
Now 10.08
- Target (low)
- 2.00
- Target (mean)
- 4.33
- Target (high)
- 7.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 3
- 1 month ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.14 | 0.13 – 0.15 | 0.31 | -54.8% | 52.50M | -27.3% | 2 |
| Next quarter | 0.06 | 0.06 – 0.06 | -0.05 | +220.0% | 47.50M | +8.5% | 1 |
| Current year | 0.50 | 0.49 – 0.51 | 0.67 | -25.4% | 223.90M | -5.0% | 2 |
| Next year | 0.595 | 0.45 – 0.74 | 0.50 | +19.0% | 221.35M | -1.1% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 26, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 20, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 4, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 5, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 6, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Aug 5, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 6, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 28, 2021 | Citigroup | Upgrade | Neutral | Buy |
| Aug 6, 2021 | RBC Capital | Maintained | — | Sector Perform |
| Aug 6, 2021 | Goldman Sachs | Maintained | — | Sell |
| Aug 10, 2020 | Citigroup | Maintained | — | Neutral |
| Aug 7, 2020 | SVB Leerink | Maintained | — | Market Perform |
| May 20, 2020 | Cantor Fitzgerald | Maintained | — | Neutral |
| Dec 6, 2019 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 8, 2019 | Goldman Sachs | Downgrade | Neutral | Sell |
| Aug 9, 2019 | Barclays | Maintained | — | Underweight |
| May 10, 2019 | Citigroup | Downgrade | Buy | Neutral |
| May 10, 2019 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Mar 1, 2019 | Citigroup | Maintained | Buy | Buy |